Jump to content

Lung cancer drug helps majority in study

Recommended Posts



May 13, 2005 — CHICAGO (Reuters) - An experimental drug to treat lung cancer appeared to benefit two-thirds of patients who used it, according to a study presented on Friday by manufacturer Telik Inc., pushing shares up as much as 17 percent.

The compound, Telcyta, aims to treat non-small cell lung cancer, one of the deadliest and poorly treated types of cancer.

Among 13 patients who took the medication along with a standard chemotherapy combination, seven experienced a partial response, and one patient had a complete response.

Results were presented at the American Society of Clinical Oncology meeting in Orlando, Florida.

Shares were up 35 cents, or 2.1 percent, at $17.35 in afternoon Nasdaq trade after rising as high as $19.87 earlier in the session. a

Copyright 2005 Reuters News Service. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.